COD Research is a leading CRO based in the US and India, specializing in global clinical trials and pharmacovigilance services. With a strong focus on biosimilar trials worldwide, we offer tailored solutions, ensuring quality, compliance, and client satisfaction. Our commitment is to contribute to the advancement of healthcare by delivering reliable and efficient services on an international scale. | We are a technical full-service Contract Research Organization (CRO) that offers end-to-end Clinical Trial Services, complemented by an industry-leading suite of specialized Pharmacovigilance Solutions. Our flexible working models are designed to seamlessly integrate with your teams, whether you require functional services for global studies or tailored on-site and off-site support. | We are a technical Full Service CRO that offers end-to-end Clinical Trial Services, complemented by an industry-leading suite of specialized Pharmacovigilance Solutions. Our flexible working models are designed to seamlessly adapt to client requirements, whether you require functional solutions or global studies or tailored on-site and off-site support.
ChomiX Biotech Co., Ltd.
The mission of ChomiX Biotech is to meet the unmet demands in the realms of biopharmaceuticals and precision medicine, through the development and provision of cutting-edge technologies in the areas of small molecule drugs, chemoproteomics, and drug discovery. | ChomiX Biotech is the first platform-based drug discovery company in China powered by live-cell chemoproteomics. The company specializes in drug screening in live-cell systems and the discovery of novel targets for bioactive drug molecules. Positioned as a “High-Value Drug Discovery Engine,” ChomiX Biotech adopts a dual-engine strategy combining platform partnerships and internal pipeline development. Leveraging its proprietary platform technologies, the company continuously advances drug discovery programs to demonstrate platform value, while engaging in deep collaborations with global pharmaceutical and biotech partners through out-licensing and co-development of internally developed pipelines.
CheckImmune GmbH
CheckImmune is an innovative immune biomarker CRO for preclinical and clinical programs. As a spin-off company of Charité Universitätsmedizin Berlin we have strong links to academic state-of-the art research. CheckImmune is providing biomarker studies with focus on novel immunotherapeutics (small molecules, biologics, Advanced Therapy Medicinal Products – ATMPs) and immunological challenges in other medical areas. CheckImmune is specialized in the development and validation of immunological biomarkers for global clinical trials and accredited according to ISO 17025 and 15189 with fulfilling the requirements of GCLP (Good Clinical Laboratory Practice). Our core expertise includes assay development and validation for Receptor Occupancy, Flow Cytometry, Multiplex Cytokine Analyses, Functional Tests, Single Cell Multiomics, and Tissue Biopsies. We are a certified service provider for 10x Genomics, Olink, and ProteinSimple Ella. We are a team of well recognized experts for immune biomarker analyses and data interpretation. Our Services are Selection/validation of drug lead candidates, Phase 0 studies with access to fresh patient material, Therapy monitoring (safety, efficacy/stratification) and Data analysis and scientific & medical interpretation. At CheckImmune, we develop highly specialized immunological biomarker assays and provide end-to-end lab services for clinical and preclinical trials. From assay design to regulatory-grade data analysis – we help biopharma companies understand immune responses with precision. We are a certified service provider for 10x Genomics, OLINK and bio-techne. With a track record of more than 90 industry-sponsored trials and 120,000 samples we have earned an excellent international reputation. Selection/validation of drug lead candidates Application of a broad panel of customized and off-the-shelf biomarker tests using cutting-edge technologies for lead candidate selection. Phase 0 studies with access to fresh patient material Proof-of-concept studies on biosamples from target patient populations (phase 0) to develop and confirm selected biomarker test portfolios for following therapy monitoring. Therapy monitoring Therapy monitoring in clinical trials to check safety, PD/PK, patient stratification with a wide range of validated assays as well as newly developed customized methods. Data analysis and scientific & medical interpretation CheckImmune is backed by a world-renowned team of experts with years of academic and commercial experience in the field of immune biomarkers. Technology used Our Technology platforms are – Complex Flow & Spectral Cytometry – Molecular & Multi-Omics Analysis: Bulk RNAseq, TCR /BCR repertoire, Single cell Multiomics (RNAseq, TCRseq, CITEseq) Spatial multi-omics, qRT- PCR (e.g. IFN signature) and digitalPCR – Multiplex Ligand Assays (MSD, Ella, OLINK) – Functional Assays – Anti-Drug Response (ADA/ADT)
CatSci
Spun out of AstraZeneca in 2010, CatSci is an award-winning innovation partner, dedicated to breaking down silos in drug development to accelerate the delivery of life-changing medicines. They proudly serve customers across the globe, delivering perfect-for-purpose solutions that balance timelines and resources with maximum flexibility. CatSci’s tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, they provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. They have specialist facilities in Process R&D, catalysis, high pressure reactions, crystallisation, pre-formulation, analytical development, HPAPI development and non-GMP material supply, and recently launched their oligonucleotides capability. Through their partnership with AGC Pharma Chemicals, they offer scalable small molecule API manufacturing, from grams to tonnes, with complete accountability of tech transfer. CatSci’s overall mission is to enable customers to create innovative therapeutics that will improve patient quality of life. They aim to become a ‘digital first, intelligent automation next’ business, freeing up the hands and minds of scientists through digital tools, enabling them to create perfect-for-purpose solutions that solve customers’ problems. Their purpose is and always will be to get medicines into the hands of patients in need. | CatSci Ltd is a UK-based award-winning innovation partner, dedicated to breaking down the silos in the development of small molecules, TACs and glues, and oligonucleotides to accelerate the delivery of life-changing medicines to patients in need. We proudly serve customers across the globe with projects, meeting their needs from candidate selection to product launch and beyond. Our tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, we provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. We possess a range of critical enabling technologies in research, development and manufacturing of small molecule and new modality therapeutics, with specialist facilities in chemical development, catalysis, material science, pre-formulation, HPAPI development, GMP analytical services, and oligonucleotide R&D and supply. Through our partnership with AGC Pharma Chemicals, we offer scalable small molecule GMP API material supply, from grams to tonnes, with seamless knowledge transfer. Agile, commercially minded and scientifically led, CatSci leverages its highly qualified technical team and state-of-the-art facilities to empower our customers to create affordable, best-in-class therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world. Recent recognition includes the 2023 UK Fast Growth 50 Index Award (Innovative Growth), the highly esteemed Queen’s Award for Enterprise: International Trade 2022, the 2022 Bionow Awards (Export of the Year), the 2022 Inspire Business Awards (Business of the Year (25+ employees)), the 2022 Wales Business Awards (Workplace Wellbeing), the 2022 Wales STEM Awards (STEM Company of the Year (50+ Employees) and STEM Ambassador of the Year), and the 2022 Cardiff Business Award (International Business of the Year). | CatSci Ltd is an award-winning innovation partner, dedicated to breaking down the silos in the CMC development of small molecules, TACS, glues, oligonucleotides and other complex medicines to accelerate the delivery of life-changing therapeutics to patients. We proudly serve customers across the globe with projects, meeting their needs from candidate selection to product launch and beyond. Our tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, we provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. We possess a range of critical enabling technologies in research, development and manufacturing of small molecule and new modality therapeutics, with specialist facilities in chemical development, catalysis, material science, pre-formulation, HPAPI development, GMP analytical services, and oligonucleotide R&D and supply. Through our partnership with AGC Pharma Chemicals, we offer scalable small molecule API manufacturing, from grams to tonnes, with complete accountability of tech transfer. Agile, commercially minded and scientifically led, CatSci leverages its highly qualified technical team and state-of-the-art facilities to empower our customers to create affordable, best-in-class therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world. Recent recognition includes the 2024 Finance Awards Wales (ESG Excellence), the 2023 UK Fast Growth 50 Index Award (Innovative Growth), the Queen’s Award for Enterprise: International Trade 2022, the 2022 Bionow Awards (Export of the Year), the 2022 Inspire Business Awards (Business of the Year (25+ employees)), the 2022 Wales Business Awards (Workplace Wellbeing), the 2022 Wales STEM Awards (STEM Company of the Year (50+ Employees), and the 2022 Cardiff Business Award (International Business of the Year). | Spun out of AstraZeneca in 2010, CatSci is an award-winning innovation partner, dedicated to breaking down silos in drug development to accelerate the delivery of life-changing medicines. They proudly serve customers across the globe, delivering perfect-for-purpose solutions that balance timelines and resources with maximum flexibility. CatSci’s tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, they provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. They have specialist facilities in Process R&D, catalysis, high pressure reactions, crystallisation, preformulation, analytical development, HPAPI development and oligonucleotide development, they recently launched their peptide and bioscience capability.
CancerFree Biotech
CancerFree Biotech has a patented system to create patient-derived organoids (PDO) using a bionic tumor culture system, which can be used as an avatar to help physicians and patients develop the optimal cancer treatment strategy. The technology uses blood specimens, making it easy and non-intrusive, and has been successful in deriving 130+ different types of solid tumors from real-world cancer patients. CancerFree Biotech is also collaborating with pharmaceutical companies, using their PDO model to predict clinical trial outcomes during the drug development process, potentially helping to validate compounds during the preclinical and clinical trial phases. | CancerFree Biotech has developed a proprietary cancer cell culture system called E.V.A. (Ex Vivo Avatar). E.V.A. combines 3D cell culture scaffolding with AI image recognition to facilitate tumor cell proliferation. Using just 20mL of patient blood, the platform grows tumor cells to generate heterogeneous organoid models that closely mimic the patient’s internal tumor. These models allow pharmaceutical companies to identify the best candidates for clinical trials by validating the efficacy of their drugs in suppressing tumor cells from real patients. | CancerFree Biotech has developed Prometheus Lab AI, a smart-glasses platform that automates R&D lab documentation. With hands-free, real-time workflow capture, Prometheus converts visual input into structured experiment records, reducing manual errors and significantly cutting down on documentation time.
BrevisRefero
BrevisRefero, in partnership with the educational platform BrickMMO, is pleased to be showcasing an ‘Interactive Biologics CDMO Facility Constructed Exclusively from LEGO(R) Bricks’ at it’s booth (1313) at BIO2024. Join us at our booth for an immersive and educational look at the biologics manufacturing like never before! BrevisRefero is a collection of biologics professionals who share a common goal – to improve and support the management of biologics programs from concept to development, GMP manufacturing and into clinical trials for the benefit of patient and sponsor alike. Pulling from more than 100 years of collective technical biotech consulting experience, we work closely with our clients to develop realistic technical and strategic solutions to support the execution and delivery of biologics programs. BrevisRefero also hosts an RFP outsource management platform called RFP>Navigator(R) that simplifies and accelerates Sponsor’s selection of their CDMO partners. | BrevisRefero Corporation is a team of biopharma professionals with a collective 100 years of biotechnology experience who assist Innovator companies to develop and manufacture their large-molecule biologics for clinical trials and commercial markets. The company assists Innovators by partnering with them at the target molecule post discovery stage and walking with them through their product development journey. Ground-level assistive support is provided in all technical aspects of drug development – from analytical methods and process development, through to scale-up and GMP manufacturing, and every aspect in between supporting their CMC program. Utilizing the deep-seated technical experience of BrevisRefero’s full-time consultants, we have developed innovative world-class online technology tools. Our award-winning commercial product RFP>Navigator®as well as our newly developed BioBudget Champion(TM) tool help propel the biopharma industry forward. Whether it is through our technical knowledge, or its application, BrevisRefero is driven to enable Innovators to succeed in their product development journey.
Biointron
Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies. Biointron holds a leading position in the antibody expression service industry. From gene sequence to purified antibodies, our production only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 3,000 biotech and pharma companies worldwide. Contact us: +1(732)790-8340, or info@biointron.com. Visit our website: www.biointron.com | Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies. Biointron holds a leading position in the antibody expression service industry. From gene sequence to purified antibodies, our production only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 2,000 biotech and pharma companies worldwide. Contact us: +1(732)790-8340, or info@biointron.com. Visit our website: www.biointron.com